---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-126599"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:13:44.887929+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cara discontinues AD program after oral difelikefalin fails Phase 3 KIND 1 study

## Summary
- Oral difelikefalin as adjunct to TCS did not meet primary endpoint vs TCS alone in 287-patient trial.
- Cara discontinues clinical program for pruritus in atopic dermatitis.
- Late-stage programs for notalgia paresthetica and advanced CKD continue; data readouts expected 2H24.
- Cara expects ~$100M cash at year-end 2023, including $20M milestone payment from HealthCare Royalty.

## SEC filing metadata
- accession: 0001104659-23-126599
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465923126599/0001104659-23-126599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465923126599/tm2333104d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-126599
- JSON: https://secwatch.observer/filing/0001104659-23-126599.json
- Plain text: https://secwatch.observer/filing/0001104659-23-126599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.